医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Mitsui Chemicals Develops AIRYFA™The World’s First Flexible Nonwoven with High Strength

2017年05月25日 PM01:32
このエントリーをはてなブックマークに追加


 

TOKYO

Mitsui Chemicals, Inc. (Tokyo: 4183; President & CEO: Tsutomu Tannowa) has successfully developed AIRYFA™, the world’s first flexible nonwoven with high strength by exploiting its proprietary polyolefin spinning technology.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170524006380/en/

New technology of AIRYFA (Graphic: Business Wire)

New technology of AIRYFA (Graphic: Business Wire)

AIRYFA™ is a high-performance nonwoven that is gentle on skin, simultaneously materializing softness and strength. By capitalizing on the company’s proprietary polyolefin spinning technology and producing this thin textile with a hollow structure that is characterized by a superior soft feeling and evenness, Mitsui Chemicals has simultaneously realized both softness and strength, which the conventional technology could not achieve.

This is an eco-friendly nonwoven that takes global environmental issues into consideration since the thin textile with a hollow structure reduces the amount of plastic used as a raw material. The name AIRYFA™ is intended to represent airy (very light and soft) fabric.

Mitsui Chemicals has developed various high-performance nonwovens, such as bulky and highly flexible nonwovens, nonwovens with excellent elasticity, and the new nonwoven AIRYFA™ for sanitary goods, including disposable diapers. To reinforce its leadership in Asia, Mitsui Chemicals, as a solution provider capable of meeting customers’ requests for quality improvement, will continue to contribute to an enhanced Quality of Life (QOL) while further developing new high-performance nonwovens.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170524006380/en/

CONTACT

Mitsui Chemicals, Inc.
Takashi Kawamoto, +81-3-6253-2100
Corporate
Communications Division

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Samsung Bioepis’ Imraldi® (Adalimumab) Recommended for Approval by European Medicines Agency
  • BionextがBiosightを市場投入:医薬品研究に革命をもたらすオンラインプラットフォーム
  • Takeda Presents Data from Phase 1/2 Studies for NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma Patients and in the Maintenance Setting
  • 2017世界移动大会-上海参展商概况
  • 新研究比较Masimo下一代SedLine®患者状态指数(PSi)与原初Psi在麻醉期间的性能